BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2023-10
216 industry Phase 2/3 trial readout(s) and 44 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2023-10 est. | P1/P2 | Tyme, Inc | NCT02562612 Study of SM-88 in Advanced Cancers | Breast Cancer | withdrawn | |
| 2023-10 est. | P3 | EMS | NCT03766750 Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. | Type2 Diabetes Mellitus | withdrawn | |
| 2023-10 est. | P3 | Shanghai Henlius Biotech | NCT04139135 A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | Gastric Cancer | unknown | 642 |
| 2023-10 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05117658 Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | NSCLC | unknown | 83 |
| 2023-10 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05339802 A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections | Skin Infection | unknown | 90 |
| 2023-10 est. | P3 | AIM Vaccine Co., Ltd. | NCT05428592 Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad | SARS-CoV-2 | unknown | 1100 |
| 2023-10 est. | P3 | Chong Kun Dang Pharmaceutical | NCT05526703 Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy | Essential Hypertension | unknown | 108 |
| 2023-10 est. | P3 | National Vaccine and Serum Institute, China | NCT05599516 Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial | COVID-19; Coronavirus Infections | unknown | 16000 |
| 2023-10 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT05602129 A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjec | Renal Replacement Therapy | unknown | 156 |
| 2023-10 est. | P3 | Palvella Therapeutics, Inc. PVLA | NCT05643872 A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita | Pachyonychia Congenita | recruiting | 45 |
| 2023-10 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT05823246 Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | Melanoma; Urothelial Carcinoma | unknown | 66 |
| 2023-10-01 est. | P3 | Neutec Ar-Ge San ve Tic A.Ş | NCT03729258 Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. | Sinusitis; Sinusitis, Acute; Rhinosinusitis; Rhinosinusitis Acute; Sinus Infection | unknown | 100 |
| 2023-10-01 est. | P3 | Shanghai Henlius Biotech | NCT03952403 A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non- | Carcinoma; Non-Small-Cell Lung | unknown | 643 |
| 2023-10-01 | P3 | Rain Oncology Inc | NCT04979442 Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | Dedifferentiated Liposarcoma | terminated | 175 |
| 2023-10-01 | P1/P2 | ZEO ScientifiX, Inc. ZEOX | NCT05228899 Zofin to Treat COVID-19 Long Haulers | COVID-19 | completed | 18 |
| 2023-10-01 est. | P1/P2 | China National Biotec Group Company Limited | NCT05365724 A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above | COVID-19 | unknown | 280 |
| 2023-10-01 est. | P3 | Zhejiang Teruisi Pharmaceutical Inc. | NCT05378867 A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC | Metastatic Colorectal Cancer (CRC) | unknown | 126 |
| 2023-10-01 | P2 | Kinarus AG | NCT05659459 The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 | COVID-19 | terminated | 17 |
| 2023-10-01 | P1/P2 | Suzhou Junjing BioSciences Co., Ltd. | NCT05662670 A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer | Locally Advanced or Metastatic NSCLC | terminated | 14 |
| 2023-10-02 | P2 | Novartis Pharmaceuticals NVS | NCT01863745 Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | Gastrointestinal Stromal Tumors | completed | 15 |
| 2023-10-02 | P2 | Pfizer PFE | NCT02850406 Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease | Sickle Cell Disease | terminated | 147 |
| 2023-10-02 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT03277196 A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation | Cystic Fibrosis | completed | 86 |
| 2023-10-02 | P3 | Merck Sharp & Dohme LLC MRK | NCT03884101 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | Endometrial Neoplasms | completed | 842 |
| 2023-10-02 | P3 | GlaxoSmithKline | NCT04246047 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Re | Multiple Myeloma | active not recruiting | 494 |
| 2023-10-02 | P3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | NCT04338022 Study of Evobrutinib in Participants With RMS (evolutionRMS 1) | Relapsing Multiple Sclerosis | terminated | 1124 |
| 2023-10-02 | P3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | NCT04338061 Study of Evobrutinib in Participants With RMS (evolutionRMS 2) | Relapsing Multiple Sclerosis | terminated | 1166 |
| 2023-10-02 | P3 | Boston Scientific Corporation BSX | NCT04647253 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) | In-Stent Restenosis | active not recruiting | 600 |
| 2023-10-02 | P2 | AbbVie ABBV | NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration; Wet Macular Degeneration; Wet Age-related Macular Dege | completed | 60 |
| 2023-10-02 | P3 | Merck Sharp & Dohme LLC MRK | NCT04865289 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | Endometrial Neoplasms | completed | 130 |
| 2023-10-02 | P2 | Sagimet Biosciences Inc. SGMT | NCT04906421 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | completed | 168 |
| 2023-10-02 | P2 | NFlection Therapeutics, Inc. | NCT05005845 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | Cutaneous Neurofibroma; Neurofibromatosis 1 | completed | 199 |
| 2023-10-02 | P3 | SK Bioscience Co., Ltd. | NCT05007951 Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) | Covid19 | completed | 4036 |
| 2023-10-02 | P3 | Gedeon Richter Plc. | NCT05087030 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis | Postmenopausal Osteoporosis | completed | 473 |
| 2023-10-02 | P2 | Zydus Therapeutics Inc. | NCT05211284 Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US | Nonalcoholic Fatty Liver Disease | terminated | 4 |
| 2023-10-02 | P2 | Incyte Corporation INCY | NCT05593432 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus | Cutaneous Lichen Planus | completed | 64 |
| 2023-10-02 | P3 | Pfizer PFE | NCT05875727 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. | Pneumococcal Disease | completed | 405 |
| 2023-10-03 | P2 | Acurx Pharmaceuticals Inc. ACXP | NCT04247542 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection | Clostridium Difficile Infection | completed | 53 |
| 2023-10-03 | P2 | ITB-Med LLC | NCT04311632 A Dose Escalation Study in de Novo Renal Transplantation | Kidney Transplantation | completed | 13 |
| 2023-10-03 | P3 | Janssen Research & Development, LLC | NCT04513912 A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With | Depressive Disorder, Major | completed | 757 |
| 2023-10-03 | P2 | Highlight Therapeutics | NCT04570332 BO-112 With Pembrolizumab in Unresectable Malignant Melanoma | Melanoma | completed | 42 |
| 2023-10-03 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT04659174 An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) | Schizophrenia | completed | 152 |
| 2023-10-03 | P2 | Dynavax Technologies Corporation | NCT05506969 Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age | Plague, Pneumonic; Plague; Vaccine-Preventable Diseases | completed | 200 |
| 2023-10-03 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT05513391 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years | Influenza Immunization | terminated | 366 |
| 2023-10-04 | P1/P2 | Kyowa Kirin Pharmaceutical Development Ltd | NCT04188964 Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age | X-linked Hypophosphatemia (XLH) | completed | 16 |
| 2023-10-04 | P2 | BioCryst Pharmaceuticals BCRX | NCT04702568 A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria; PNH | terminated | 19 |
| 2023-10-04 | P3 | BioNTech SE BNTX | NCT04816643 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children | SARS-CoV-2 Infection, COVID-19 | completed | 11837 |
| 2023-10-04 est. | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT04951648 A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced o | Non-small Cell Lung Cancer | unknown | 220 |
| 2023-10-04 | P3 | Sarepta Therapeutics, Inc. SRPT | NCT05096221 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (D | Duchenne Muscular Dystrophy | completed | 126 |
| 2023-10-04 | P2 | AstraZeneca AZN | NCT05375760 A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and P | Coronavirus Disease 2019 (COVID-19) | terminated | 251 |
| 2023-10-04 | P3 | Croma-Pharma GmbH | NCT05386030 Saypha® VOLUME Lidocaine for Midface Augmentation | Moderate to Severe Midface Volume Deficit | completed | 562 |
| 2023-10-04 | P2 | Sention Therapeutics, LLC | NCT05412979 A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism | Hypothyroidism | completed | 490 |
| 2023-10-05 | P3 | Hoffmann-La Roche | NCT02118584 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies | Ulcerative Colitis | terminated | 1822 |
| 2023-10-05 | P2 | Pfizer PFE | NCT03845517 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Systemic Lupus Erythematosus | completed | 350 |
| 2023-10-05 | P2 | Hoffmann-La Roche | NCT04075266 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | active not recruiting | 23 |
| 2023-10-05 | P1/P2 | Bristol-Myers Squibb BMY | NCT04446650 A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), | Primary Myelofibrosis | completed | 31 |
| 2023-10-05 | P2 | Hoffmann-La Roche | NCT05401565 Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD) | Stress Disorders, Post-Traumatic | completed | 29 |
| 2023-10-05 | P2/P3 | Cessatech A/S | NCT05508594 Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 | Pain | completed | 220 |
| 2023-10-06 | P2 | Novo Nordisk A/S NVO | NCT04204408 A Research Study Investigating Mim8 in People With Haemophilia A | Healthy Volunteers; Haemophilia A With or Without Inhibitors | completed | 275 |
| 2023-10-06 | P2 | Harmony Biosciences Management, Inc. HRMY | NCT04886518 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | Myotonic Dystrophy 1; Excessive Daytime Sleepiness | completed | 30 |
| 2023-10-06 | P1/P2 | Paean Biotechnology Inc. | NCT04976140 Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis | Polymyositis; Dermatomyositis | completed | 9 |
| 2023-10-06 | P3 | Bio-Thera Solutions | NCT05046431 Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis | Psoriatic Arthritis | completed | 704 |
| 2023-10-06 | P2 | Pfizer PFE | NCT05061446 Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | completed | 54 |
| 2023-10-06 | P1/P2 | LaNova Medicines Limited | NCT05255484 Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | Advanced Solid Tumor | terminated | 24 |
| 2023-10-06 | P2 | Definium Therapeutics US, Inc. DFTX | NCT05407064 A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms | Anxiety Generalized | completed | 198 |
| 2023-10-06 | P3 | AbbVie ABBV | NCT05878067 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants | Dry Eye Syndrome | completed | 40 |
| 2023-10-06 | P3 | Ocumension Therapeutics (Suzhou) Co., Ltd | NCT06697522 Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children | Myopia | completed | 148 |
| 2023-10-08 | P3 | Boehringer Ingelheim | NCT04915729 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity | Stroke | completed | 1489 |
| 2023-10-08 | P2 | Tonix Pharmaceuticals, Inc. TNXP | NCT05679908 A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine | Chronic Migraine; Chronic Migraine, Headache; Chronic Migraine Without Aura; Aura Migraine | completed | 88 |
| 2023-10-08 | P2/P3 | Jiaxing AnDiCon Biotech Co.,Ltd | NCT06342921 ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection | Safety Issues; Effect of Drug | completed | 749 |
| 2023-10-09 | P3 | Hoffmann-La Roche | NCT02403323 Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 | Crohn Disease | terminated | 790 |
| 2023-10-09 | P1/P2 | Laekna Limited | NCT03843918 A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer | Prostate Cancer Metastatic | terminated | 33 |
| 2023-10-09 | P3 | argenx ARGX | NCT04687072 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | completed | 207 |
| 2023-10-09 | P2 | EsoCap AG | NCT04849390 A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | completed | 43 |
| 2023-10-09 | P3 | Inmunotek S.L. | NCT04874714 Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis | Allergic Rhinoconjunctivitis; Perennial Allergic Rhinitis; House Dust Mite Allergy; Pollen Allergy | terminated | 18 |
| 2023-10-09 | P3 | Lakefront Biotherapeutics NV LKFT | NCT05479058 A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission | Ulcerative Colitis | terminated | 22 |
| 2023-10-10 | P3 | GlaxoSmithKline | NCT04010539 A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea | Gonorrhea | completed | 628 |
| 2023-10-10 | P3 | EMS | NCT04185441 Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia | Erectile Dysfunction; Benign Prostatic Hyperplasia | completed | 295 |
| 2023-10-10 | P2 | AstraZeneca AZN | NCT04277546 Open-label Extension Study of Brazikumab in Ulcerative Colitis | Ulcerative Colitis | terminated | 57 |
| 2023-10-10 | P2 | Arrevus Inc. | NCT05105035 Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients | Melioidosis | completed | 125 |
| 2023-10-10 | P2 | Janssen Research & Development, LLC | NCT05653427 A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma | Carcinoma, Hepatocellular | terminated | 18 |
| 2023-10-10 | P1/P2 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT05779995 A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV | RSV Infection | completed | 61 |
| 2023-10-11 | P2 | Merck Sharp & Dohme LLC MRK | NCT03776136 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/ | Advanced Melanoma | completed | 103 |
| 2023-10-11 | P3 | Hoffmann-La Roche | NCT04432831 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema | Diabetic Macular Edema | completed | 1479 |
| 2023-10-11 | P3 | Novo Nordisk A/S NVO | NCT04916470 Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | completed | 617 |
| 2023-10-11 | P1/P2 | Allogene Therapeutics ALLO | NCT05000450 Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | terminated | 6 |
| 2023-10-11 | P2 | Merck Sharp & Dohme LLC MRK | NCT05008224 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | Classical Hodgkin Lymphoma | completed | 146 |
| 2023-10-11 | P1/P2 | Pfizer PFE | NCT05261490 Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Canc | terminated | 10 |
| 2023-10-11 | P3 | Sylentis, S.A. | NCT05310422 Safety Study of Tivanisiran to Treat Dry Eye | Dry Eye Disease | completed | 301 |
| 2023-10-11 | P3 | Opus Genetics, Inc IRD | NCT05646719 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia | Presbyopia | completed | 333 |
| 2023-10-12 | P1/P2 | Hoffmann-La Roche | NCT03677141 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzu | B-cell Non-Hodgkin Lymphoma | completed | 117 |
| 2023-10-12 | P2 | Kite, A Gilead Company | NCT03761056 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | B-cell Lymphoma | completed | 42 |
| 2023-10-12 | P1/P2 | Dizal Pharmaceuticals | NCT04105010 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Relapsed or Refractory Peripheral T Cell Lymphoma | completed | 171 |
| 2023-10-12 | P2 | Novartis Pharmaceuticals NVS | NCT04677595 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | Non-Small Cell Lung Cancer (NSCLC) | completed | 36 |
| 2023-10-12 | P2/P3 | Sumitomo Pharma Co., Ltd. | NCT04825860 A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase | Schizophrenia | terminated | 83 |
| 2023-10-12 | P2 | Boehringer Ingelheim | NCT05103657 A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder | Post-Traumatic Stress Disorder | completed | 318 |
| 2023-10-12 | P3 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | NCT05151328 Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation | Functional Constipation | completed | 648 |
| 2023-10-12 | P2 | Novo Nordisk A/S NVO | NCT05486065 A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight | Diabetes Mellitus, Type 2 | completed | 245 |
| 2023-10-12 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT05660538 Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathy | completed | 194 |
| 2023-10-13 | P2/P3 | Geron Corporation GERN | NCT02598661 Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome ( | Myelodysplastic Syndromes | active not recruiting | 289 |
| 2023-10-13 | P1/P2 | ViaCyte | NCT03163511 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness | Type 1 Diabetes Mellitus With Hypoglycemia | completed | 49 |
| 2023-10-13 | P1/P2 | Incyte Corporation INCY | NCT03978637 Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation | Bronchiolitis Obliterans Syndrome | terminated | 23 |
| 2023-10-13 | P3 | Lee's Pharmaceutical Limited | NCT04878016 A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC | Extensive-stage Small-cell Lung Cancer | completed | 498 |
| 2023-10-13 est. | P3 | Shandong New Time Pharmaceutical Co., LTD | NCT05040906 A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | Recruiting | unknown | 416 |
| 2023-10-13 | P2 | Azura Ophthalmics | NCT05548491 Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD) | Contact Lens Discomfort | completed | 67 |
| 2023-10-13 | P3 | Braintree Laboratories | NCT05587322 A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease | Non-erosive Reflux Disease | completed | 788 |
| 2023-10-15 est. | P2/P3 | Bausch Health Americas, Inc. | NCT04083651 A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Pancreatic Cancer | withdrawn | |
| 2023-10-15 est. | P3 | Shanghai Henlius Biotech | NCT04465734 A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Adv | Hepatocellular Carcinoma (HCC) | withdrawn | |
| 2023-10-15 | P2 | Rain Oncology Inc | NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors | Solid Tumors; Head and Neck Carcinoma; Cholangiocarcinoma; Sarcoma; Lung Adenocarcinoma; Bladder Uro | terminated | 40 |
| 2023-10-15 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05020652 A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis | Moderate and High Risk Myelofibrosis | completed | 107 |
| 2023-10-16 | P2 | Cardiff Oncology CRDF | NCT03414034 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | completed | 72 |
| 2023-10-16 | P2 | Entero Therapeutics | NCT04243551 Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients | Celiac Disease | terminated | 83 |
| 2023-10-16 | P3 | Novo Nordisk A/S NVO | NCT04998136 Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity | completed | 150 |
| 2023-10-16 | P1/P2 | Cybin IRL Limited | NCT05385783 A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder | Major Depressive Disorder | completed | 57 |
| 2023-10-16 | P2 | Vaxart VXRT | NCT05626803 A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers | Norovirus Infections | completed | 135 |
| 2023-10-16 | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06715319 Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis | PBC | completed | 100 |
| 2023-10-17 | P3 | BeiGene | NCT04866017 A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non | Non Small Cell Lung Cancer | terminated | 63 |
| 2023-10-17 | P3 | Incyte Corporation INCY | NCT05073458 Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | terminated | 13 |
| 2023-10-17 | P2 | Medipost Co Ltd. | NCT05182034 Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis | Knee Osteoarthritis | completed | 94 |
| 2023-10-17 | P3 | Aerie Pharmaceuticals | NCT05360966 Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3) | Dry Eye Disease | completed | 467 |
| 2023-10-18 | P2 | Regeneron Pharmaceuticals REGN | NCT02760498 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | completed | 432 |
| 2023-10-18 | P2/P3 | AstraZeneca AZN | NCT03759288 An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease; IBD | terminated | 89 |
| 2023-10-18 | P1/P2 | Kolon Life Science | NCT04238793 Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Neuropathic Pain From Lumbosacral Radiculopathy | completed | 18 |
| 2023-10-18 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT04617028 Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis | Myelofibrosis | completed | 105 |
| 2023-10-18 | P2 | Achilles Therapeutics UK Limited | NCT04785365 Long-Term Follow-Up Study of Patients Receiving ATL001 | Melanoma; Advanced Non Small Cell Lung Cancer | terminated | 1 |
| 2023-10-18 | P1/P2 | PureTech PTCHF | NCT05129865 LYT-300 in Healthy Volunteers | Healthy Volunteers | completed | 186 |
| 2023-10-18 | P3 | Sumitomo Pharma America, Inc. | NCT05169710 A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. | Depressive Episodes, Bipolar I Depression | terminated | 83 |
| 2023-10-18 | P2 | Neurocrine UK Limited NBIX | NCT05222152 Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency | Primary Adrenal Insufficiency | completed | 58 |
| 2023-10-18 | P2 | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | NCT05291689 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC | Inflammatory Bowel Diseases; Colitis, Ulcerative | completed | 39 |
| 2023-10-19 | P1/P2 | Autolus Limited AUTL | NCT03287817 Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | 52 |
| 2023-10-19 | P2 | Pfizer PFE | NCT03395184 Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease | Crohn's Disease | completed | 244 |
| 2023-10-19 | P2 | Oncotherapeutics | NCT03733691 Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Newly Diagnosed Multiple Myeloma | terminated | 19 |
| 2023-10-19 | P3 | NS Pharma, Inc. | NCT04060199 Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) | Duchenne Muscular Dystrophy | completed | 77 |
| 2023-10-19 | P2 | Janssen Research & Development, LLC | NCT04535544 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus | Hepatitis D, Chronic | completed | 52 |
| 2023-10-19 | P2 | Pulmocide Ltd | NCT05037851 An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Stu | Pulmonary Aspergillosis | completed | 102 |
| 2023-10-19 | P3 | Veru Inc. VERU | NCT05065411 Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | terminated | 5 |
| 2023-10-19 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT05194124 Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | completed | 19 |
| 2023-10-19 | P2/P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05375305 A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery | Pain | completed | 320 |
| 2023-10-19 | P2 | Incyte Corporation INCY | NCT05635838 Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 69 |
| 2023-10-19 | P2 | Merz Aesthetics GmbH | NCT05773053 A Study of NT 201 Doses in the Treatment of Platysma Prominence | Platysma Prominence | completed | 73 |
| 2023-10-19 | P2 | Longbio Pharma | NCT06046391 Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult | Seasonal Allergic Rhinitis | completed | 180 |
| 2023-10-20 | P2/P3 | Janssen Research & Development, LLC | NCT03466411 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | active not recruiting | 1409 |
| 2023-10-20 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT03691610 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants | Healthy Volunteers (Meningococcal Infection) | completed | 950 |
| 2023-10-20 | P3 | Gilead Sciences GILD | NCT03901339 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | completed | 543 |
| 2023-10-20 | P2 | HemoShear Therapeutics | NCT04732429 Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia | Methylmalonic Acidemia; Propionic Acidemia | terminated | 26 |
| 2023-10-20 | P2 | BeiGene | NCT05014828 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors | Advanced Solid Tumor | completed | 58 |
| 2023-10-20 | P2 | LEO Pharma | NCT05388760 Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) | Atopic Dermatitis | completed | 28 |
| 2023-10-20 | P3 | Sanofi SNY | NCT05413369 iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) | Type 2 Diabetes Mellitus | completed | 582 |
| 2023-10-20 | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05536726 A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis | Psoriasis | completed | 458 |
| 2023-10-20 | P2 | Noema Pharma AG | NCT05583955 A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) | Childhood-Onset Fluency Disorder | completed | 75 |
| 2023-10-20 | P2/P3 | Taisho Pharmaceutical Indonesia | NCT07482046 Effectiveness of Topical Menthol as A Cooling Method During Exercise in A Recreational Runner Population | Heat Stress; Athletic Performance | completed | 37 |
| 2023-10-22 | P1/P2 | Gan and Lee Pharmaceuticals, USA | NCT06256536 A Study of GZR18 Injection in Chinese Obese/Overweight Patients | Obesity; Overweight | completed | 60 |
| 2023-10-23 | P3 | Celgene | NCT03575351 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressiv | Lymphoma, Non-Hodgkin | completed | 184 |
| 2023-10-23 | P2 | AstraZeneca AZN | NCT03616821 Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis; IBD | terminated | 242 |
| 2023-10-23 | P2 | Anterogen Co., Ltd. | NCT03754465 Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers | Diabetic Foot Ulcer | completed | 66 |
| 2023-10-23 | P2 | Janssen Research & Development, LLC | NCT04523207 A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metasta | Prostatic Neoplasms | completed | 108 |
| 2023-10-23 | P1/P2 | Amgen AMGN | NCT04631601 Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | terminated | 55 |
| 2023-10-23 | P2 | Janssen Research & Development, LLC | NCT04968912 A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) | Sjogren's Syndrome | completed | 163 |
| 2023-10-23 | P2 | Eli Lilly and Company LLY | NCT05565742 A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] | Lipoprotein Disorder | completed | 320 |
| 2023-10-23 | P2 | Xiamen Amoytop Biotech Co., Ltd. | NCT05838885 A Trial of YPEG-rhGH in Children With Short Stature | Idiopathic Short Stature; Small for Gestational Age; Turner Syndrome | completed | 78 |
| 2023-10-25 est. | P1/P2 | Haihe Biopharma Co., Ltd. | NCT04270591 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | C-Met Exon 14 Mutation | recruiting | 183 |
| 2023-10-25 | P2 | Shanghai Ming Ju Biotechnology Co., Ltd. | NCT04718883 CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | Mantle Cell Lymphoma | active not recruiting | 59 |
| 2023-10-25 | P3 | Takeda TAK | NCT05543174 A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Alagille Syndrome (ALGS) | completed | 7 |
| 2023-10-25 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05628311 A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Type 2 Diabetes | completed | 319 |
| 2023-10-26 | P2/P3 | SyneuRx International (Taiwan) Corp | NCT01908192 Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® | Schizophrenia | terminated | 60 |
| 2023-10-26 | P3 | Pfizer PFE | NCT02791230 Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy | Transthyretin (TTR) Amyloid Cardiomyopathy | completed | 1733 |
| 2023-10-26 | P1/P2 | Eisai Inc. | NCT03250676 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | Breast Neoplasms; Breast Cancer; Estrogen-receptor Positive Breast Cancer; Cancer, Breast; Breast Ca | completed | 151 |
| 2023-10-26 est. | P2 | Pfizer PFE | NCT04209556 A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis | Ulcerative Colitis | withdrawn | |
| 2023-10-26 | P3 | AstraZeneca AZN | NCT04612790 A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | Bullous Pemphigoid | terminated | 67 |
| 2023-10-26 | P1/P2 | Akeso | NCT04646330 A Trial of AK104 Plus Anlotinib in NSCLC | NSCLC | completed | 114 |
| 2023-10-26 | P1/P2 | XBiotech, Inc. XBIT | NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer | Pancreatic Cancer | completed | 76 |
| 2023-10-26 | P2 | Novartis Pharmaceuticals NVS | NCT04878432 STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | Myelodysplastic Syndrome (MDS) | terminated | 39 |
| 2023-10-26 | P2/P3 | Alexion Pharmaceuticals, Inc. | NCT04999020 Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | Dermatomyositis | terminated | 38 |
| 2023-10-26 | P3 | Ferrer Internacional S.A. | NCT05178810 Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | completed | 313 |
| 2023-10-26 est. | P2 | Inmune Bio, Inc. INMB | NCT05321498 Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation | Mild Cognitive Impairment (MCI); Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System | withdrawn | |
| 2023-10-26 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT05432596 Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 250 |
| 2023-10-26 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05447663 A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | Acute Myeloid Leukemia; Allogeneic Stem Cell Transplantation | terminated | 8 |
| 2023-10-26 | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05905614 Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors | Advanced Solid Tumors | completed | 29 |
| 2023-10-26 | P3 | Sinovac Life Sciences Co., Ltd. | NCT06049940 Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population | Tetanus | completed | 1260 |
| 2023-10-27 | P2 | AstraZeneca AZN | NCT00378482 A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially A | Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms; Patients Who H | completed | 37 |
| 2023-10-27 | P1/P2 | OBI Pharma, Inc | NCT04084366 Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | Locally Advanced Solid Tumor | terminated | 44 |
| 2023-10-27 | P3 | Pfizer PFE | NCT04424316 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. | Respiratory Tract Infection | completed | 14727 |
| 2023-10-27 | P2 | Novartis Pharmaceuticals NVS | NCT05111249 A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease | Early Manifest Huntington Disease | terminated | 26 |
| 2023-10-27 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT05513053 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. | Influenza Immunization | completed | 1308 |
| 2023-10-27 | P3 | Acrotech Biopharma Inc. | NCT05608343 This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD) | Atopic Dermatitis | completed | 153 |
| 2023-10-30 | P2 | PTC Therapeutics PTC | NCT02352896 Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome | Leigh Syndrome | completed | 30 |
| 2023-10-30 | P3 | Merck Sharp & Dohme LLC MRK | NCT03493542 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young W | Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) | completed | 766 |
| 2023-10-30 | P2 | Sarepta Therapeutics, Inc. SRPT | NCT04004065 Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amena | Duchenne Muscular Dystrophy | terminated | 62 |
| 2023-10-30 | P3 | Novartis Pharmaceuticals NVS | NCT04278417 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy | Proliferative Diabetic Retinopathy | completed | 689 |
| 2023-10-30 | P3 | Novartis Pharmaceuticals NVS | NCT04659863 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | completed | 13 |
| 2023-10-30 | P1/P2 | Mereo BioPharma MREO | NCT04761198 A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Metastatic Solid Tumor | completed | 76 |
| 2023-10-30 | P2 | Oryzon Genomics S.A. | NCT04932291 Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population | Borderline Personality Disorder | completed | 211 |
| 2023-10-30 est. | P2 | Halucenex Life Sciences Inc. | NCT05243329 Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder | Treatment Resistant Disorders; Post Traumatic Stress Disorder | unknown | 20 |
| 2023-10-30 est. | P1/P2 | E2Bio Life Sciences, LLC | NCT05338398 Study for the Prevention of Oral Mucositis (SPOM) | Oral Mucositis | unknown | 100 |
| 2023-10-30 est. | P1/P2 | Keymed Biosciences Co.Ltd | NCT05465707 A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | unknown | 40 |
| 2023-10-30 | P3 | Merck Sharp & Dohme LLC MRK | NCT05569954 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) | Pneumococcal Disease | completed | 1484 |
| 2023-10-30 | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05769855 A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy | Postsurgical Pain Management | completed | 294 |
| 2023-10-30 | P2 | CNBG-Virogin Biotech (Shanghai) Ltd. | NCT06113731 A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine | SARS-CoV-2 Infection | unknown | 980 |
| 2023-10-31 | P1/P2 | Prescient Therapeutics, Ltd. | NCT02930109 A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | Acute Leukemia | completed | 33 |
| 2023-10-31 | P3 | AB2 Bio Ltd. | NCT03113760 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency | NLRC4-MAS; XIAP Deficiency | completed | 15 |
| 2023-10-31 est. | P1/P2 | Immix Biopharma Australia Pty Ltd IMMX | NCT03382340 IMX-110 in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumors; Pancreatic Cancer; Breast Cancer; Ovarian Cancer | unknown | 70 |
| 2023-10-31 | P1/P2 | BioXcel Therapeutics Inc BTAIQ | NCT03910660 A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Pr | Prostate Cancer; Neuroendocrine Tumors; Small Cell Carcinoma | completed | 97 |
| 2023-10-31 | P3 | Bristol-Myers Squibb BMY | NCT04149574 A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Mu | Urinary Bladder Neoplasms | terminated | 13 |
| 2023-10-31 | P2 | Laekna Limited | NCT04374630 Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | Platinum-resistant Ovarian Cancer | completed | 150 |
| 2023-10-31 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04385550 A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | unknown | 528 |
| 2023-10-31 est. | P2 | SafelyYou | NCT04478149 A Comprehensive Fall Prevention System for Memory Care: Final Feasibility and Randomized Controlled Study | Dementia | unknown | 300 |
| 2023-10-31 | P2 | Resolve Therapeutics | NCT04944121 Phase 2 Study of RSLV-132 in Subjects With Long COVID | Post-acute Corona Virus 19 (COVID-19) (Long COVID) | completed | 112 |
| 2023-10-31 est. | P2 | Guizhou Bailing Group Pharmaceutical Co Ltd | NCT05007262 Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy | Type2 Diabetes; Diabetic Retinopathy | unknown | 240 |
| 2023-10-31 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05027204 A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | Squamous Cell Carcinoma of Head and Neck | unknown | 94 |
| 2023-10-31 | P1/P2 | Advagene Biopharma Co. Ltd. | NCT05069610 Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19 | COVID-19 | completed | 30 |
| 2023-10-31 | P3 | Keymed Biosciences Co.Ltd | NCT05265923 A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | completed | 500 |
| 2023-10-31 est. | P3 | Jeil Pharmaceutical Co., Ltd. | NCT05296044 To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin | Type 2 Diabetes Mellitus | unknown | 245 |
| 2023-10-31 | P2 | Amgen AMGN | NCT05430854 Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study | Systemic Lupus Erythematosus | terminated | 155 |
| 2023-10-31 est. | P3 | Reistone Biopharma Company Limited | NCT05470413 Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata | Alopecia Areata | unknown | 330 |
| 2023-10-31 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05663411 A Study of SHR6508 in Secondary Hyperparathyroidism | Secondary Hyperparathyroidism | unknown | 75 |
| 2023-10-31 | P1/P2 | Valerio Therapeutics | NCT05700669 Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | Metastatic Castration-resistant Prostate Cancer; Recurrent Epithelial Ovarian Cancer; Breast Cancer | completed | 3 |
| 2023-10-31 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05961007 Evaluation of IBI302 Injection in nAMD or DME | Neovascular Age-related Macular Degeneration; Diabetic Macular Edema | suspended | 234 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.